SAN FRANCISCO— FibroGen Inc. has named Michael Martinelli, PhD, as Vice President, Technical Development.
In this role, Martinelli is responsible for the chemistry, manufacturing, and controls (CMC) development activities for FibroGen’s most advanced small molecule clinical candidates, including FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in phase 2b development for the treatment of anemia associated with chronic kidney disease.
Martinelli, who joined FibroGen in the first quarter of this year, has 25 years of drug development experience from leadership roles in pharmaceutical research & development. He most recently served as Vice President, Pharmaceutical Development, for Arena Pharmaceuticals in San Diego.
"We welcome Mike to FibroGen and are pleased to have his expertise and experience in technical development, particularly as we prepare for phase 3 development activities in our anemia program," said Thomas B. Neff, CEO of FibroGen. “In the near term, I look forward to Mike’s contributions in leading CMC efforts to ensure that development processes and manufacturing infrastructures are in place to support global development of FG-4592.”
